Press releasePRNewswire
C4 Therapeutics
CCCC · NASDAQ
$3.16+$0.27 (+9.34%)TodayMarket closed ·
Prev close $2.89
Latest news
- Press releaseGlobe Newswire
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Press releaseGlobe Newswire
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
- NewsAvi Kapoor
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
- NewsAvi Kapoor
Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results
- NewsAvi Kapoor
Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
- News
Earnings Scheduled For May 12, 2026
- Press releaseGlobe Newswire
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
- NewsVandana Singh
C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies
- News
C4 Therapeutics Teams Up With Roche On New Cancer Drug Approach, Secures $20M Upfront, Eyes Over $1B In Future Milestones
- Press releaseGlobe Newswire
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
- Press releaseGlobe Newswire
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
- Press releasePRNewswire
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
- News
Earnings Summary: C4 Therapeutics Q4
- Press releaseGlobe Newswire
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
- NewsAvi Kapoor
This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday
- NewsAvi Kapoor
This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- Press releasePRNewswire
Precision Oncology Approaches Drive $312B Market Transformation
- News
Forecasting The Future: 4 Analyst Projections For C4 Therapeutics
- Press releasePRNewswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
AT&T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday
- Press releaseBusiness Wire
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
- Press releaseBusiness Wire
Seaport Therapeutics Names Lauren White as Chief Financial Officer
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.